We are excited to see that One Nucleus Corporate Patron, AstraZeneca, has announced an ambitious goal to achieve $80 billion in annual revenue by 2030, a significant increase from $45 billion in 2023. This growth will be driven by expanding their oncology, biopharmaceuticals and rare disease portfolios and launching 20 new medicines by the end of the decade. Additionally, AstraZeneca plans to sustain growth beyond 2030 by investing in transformative new technologies. They also committed to halving carbon emissions across their value chain by 2030, demonstrating a dedication to both innovation and sustainability.